Cohance Lifesciences FY26 Revenue Declines 13% YoY

Cohance Lifesciences reported FY26 revenue of INR 22.68 Bn, a 13.0% YoY decline, with Adjusted EBITDA at INR 4.78 Bn (21.0% margin).
The company strengthened leadership under Mr. Umang Vohra and enhanced capabilities across Pharma CDMO, API+, and Specialty Chemicals segments.
FY27 is projected as a growth year weighted towards 2H, with Q1 expected to be weak due to shipment phasing and cost escalations.
Balance sheet remained strong with net cash of INR 1.53 Bn and free cash flow generation of INR 1.73 Bn for FY26.